8/9/2019 Unit 05ppt

1/48

BIOSAFETY IN THELABORATORY 

UNIT-05

8/9/2019 Unit 05ppt

2/48

8/9/2019 Unit 05ppt

3/48

8/9/2019 Unit 05ppt

4/48

8/9/2019 Unit 05ppt

5/48

8/9/2019 Unit 05ppt

6/48

BIOSAFETY LEVELS ANDRISK ASSESSMENT 

2.2.1 Biosafe! Le"e# 1 $BSL-1%2.2.2 Biosafe! Le"e# 2 $BSL-2%

2.2.& Biosafe! Le"e# & $BSL-&%2.2.' Biosafe! Le"e# ' $BSL-'%2.2.5 A(e) S*++a,! Sae+e)s2.2. Ris Assess+e)

8/9/2019 Unit 05ppt

7/48

2.2.1 Biosafe! Le"e# 1 $BSL-1%

A(e)s/ e)e a) 34a,a3e,ie s,ai)s of+i3,oo,(a)is+s )o )o6) o 3o)sise)#! 3a*seisease i) 4ea#4! a*#s e.(.7 B. subtilis7S. cerevesiae7)o)-8a4o(e)i3 E. coli . I)3#*es ,e3o+9i)a) DNAa3i"iies *si)( s*34 )o)-8a4o(e)i3 o,(a)is+s as

4oss fo, 4e e:8,essio) of (e)es i)3o,8o,ae i)o9a3e,ia# 8#as+is o, #o6 ,is "i,a# "e3o,s s*34 as9a3*#o"i,*s o, Ae)o Asso3iae Vi,*s.

;o, 8,a3i3es/ sa)a, +i3,o9io#o(i3a#

8,a3i3es

8/9/2019 Unit 05ppt

8/48

2.2.2 Biosafe! Le"e# 2 $BSL-2%

A(e)s/ associated with human diseases of varying severity,e.g., Hepatitis B and C, HIV, S. typhi, human retroviruses, S.aureus. Includes recombinant D! activities using viral vectorsystems such as !denoviruses and some "etroviral vectors,particularly #entiviral vectors, and e$pression of recombinantD! in B%#&' organisms.

T,a)s+issio)/ inoculation and other percutaneous in(uries,ingestion, mucous membrane e$posure

;o, 8,a3i3es/  B%#&) practices, with the addition of* limitedaccess, +Biohaard- signs, +sharps- precautions, denedprocedures for "egulated /edical 0aste 1"/02 disposal andmedical surveillance 1as needed2.

8/9/2019 Unit 05ppt

9/48

%afety e3uipment* Class I or II Biological %afetyCabinet 1B%C2 or e3uivalent containment formanipulations with potential for aerosoliation orsplashing4 lab coats, gloves, eye5face protection.

6acilities* B%#&) facilities, with the addition of*available autoclave, directional air7ow, no airrecirculation, disinfection5decontamination

procedures in place.

8/9/2019 Unit 05ppt

10/48

%afety e3uipment*

Class I or II Biological %afety Cabinet 1B%C2 ore3uivalent containment for manipulations withpotential for aerosoliation or splashing4 lab coats,gloves, eye5face protection.

6acilities*

B%#&) facilities, with the addition of* available

autoclave, directional air7ow, no air recirculation,disinfection5decontaminationprocedures in place.

8/9/2019 Unit 05ppt

11/48

2.2.& Biosafe! Le"e# & $BSL-&%!gents* serious or lethal diseases transmissible via

aerosols, e.g., M. tuberculosis, %!"%. "ecombinantD! activities using genetic material from B%#&8organisms or such organisms as host cells.

 9ransmission* aerosol inhalation, inoculation and

other percutaneous in(uries, ingestion, mucousmembrane e$posure

0or: practices* B%#&' practices, with the addition

of* controlled access, on&site decontamination of allwaste and lab clothing, medical surveillance.

%afety e3uipment* Class I or II Biological %afetyCabinet 1B%C2 or e3uivalent containment for allopen manipulations of agents4 lab coats, gloves,

8/9/2019 Unit 05ppt

12/48

6acilities*

B%#&' facilities, with the addition of* physicalseparation from access corridors, double&door entry,directional air 7ow into lab, no recirculation ofe$haust air, bac:&up ventilation and ltration

systems, in&lab autoclave

8/9/2019 Unit 05ppt

13/48

2.2.' Biosafe! Le"e# ' $BSL-'%;rganisms in this category are of such e$tremelyhigh ris: that only a handful of laboratoriesnationwide wor: at this level. o such facilitiese$ist at the

8/9/2019 Unit 05ppt

14/48

2.2.5 A(e) S*++a,! Sae+e)s

!gent %ummary %tatements, includingrecommended B%# for many laboratorymicroorganisms, are included in B/B#=.;ther resources for biosafety haard

classication are noted on the !mericanBiological %afety !ssociation 1!B%!2 page, "is:>roup Classication for Infectious !gents.

8/9/2019 Unit 05ppt

15/48

2.2. Ris Assess+e)

Biosafety #evel classications are appropriate fortypical laboratory operations. 9he ?rincipalInvestigator or laboratory director is responsible forimplementing more 1or less2 stringent practices basedon laboratory specic conditions. %uch a decision isultimately the result a ris: assessment process thataccounts for the following*

8/9/2019 Unit 05ppt

16/48

>a4o(e)i3i! - 4e a9i#i! of a) o,(a)is+ o 3a*seisease.

Vi,*#e)3e - 4e se"e,i! of isease.

T,a)s+issio) ,o*e - 8a,e)e,a#7 i)(esio)7 +*3o*s+e+9,a)e e:8os*,e7 o, i)4a#aio). T4e #ae, ,o*e isof 4e (,eaes 3o)3e,) 64i34 is 64! o,(a)is+s s*34

as M. *9e,3*#osis ,e=*i,e +o,e s,i)(e) 3o),o# 4a)o,(a)is+s 4a a,e ,a)s+ie "ia i,e3 3o)a37 e.(.7HBV.

A(e) sa9i#i! - s*,"i"a# i) e)"i,o)+e) o, o4e,6ise

8,o#o)(e "ia9i#i! $s8o,e fo,+aio)%.

I)fe3io*s ose - 4e ose ,e=*i,e o 3a*se i)fe3io)i) 4*+a)s o, a)i+a#s $ID 50 ,efe,s o 4e ose )eeeo i)fe3 50? of 4e e:8ose 8o8*#aio)%.A)i9ioi3 ,esisa)3e.

8/9/2019 Unit 05ppt

17/48

T4e *se of ,e3o+9i)a) DNA +a! a#e, a)! of 4e

a9o"e ,is fa3o,s a) i)"esi(ao,s s4o*# ae4ese +oi3aio)s i)o 3o)sie,aio) 64e)6o,i)( 6i4 ,e3o+9i)a) +i3,oo,(a)is+s.

A## of 4e a9o"e fa3o,s a,e i)4e,e) o a 8a,i3*#a,+i3,o9e@ e:e,)a# fa3o,s o 9e 3o)sie,e i) a ,isassess+e) i)3#*e/

8/9/2019 Unit 05ppt

18/48

Tie,

8/9/2019 Unit 05ppt

19/48

THANK YOU

8/9/2019 Unit 05ppt

20/48

8/9/2019 Unit 05ppt

21/48

8/9/2019 Unit 05ppt

22/48

8/9/2019 Unit 05ppt

23/48

8/9/2019 Unit 05ppt

24/48

8/9/2019 Unit 05ppt

25/48

8/9/2019 Unit 05ppt

26/48

8/9/2019 Unit 05ppt

27/48

8/9/2019 Unit 05ppt

28/48

8/9/2019 Unit 05ppt

29/48

8/9/2019 Unit 05ppt

30/48

8/9/2019 Unit 05ppt

31/48

8/9/2019 Unit 05ppt

32/48

8/9/2019 Unit 05ppt

33/48

8/9/2019 Unit 05ppt

34/48

8/9/2019 Unit 05ppt

35/48

8/9/2019 Unit 05ppt

36/48

8/9/2019 Unit 05ppt

37/48

8/9/2019 Unit 05ppt

38/48

8/9/2019 Unit 05ppt

39/48

8/9/2019 Unit 05ppt

40/48

8/9/2019 Unit 05ppt

41/48

8/9/2019 Unit 05ppt

42/48

8/9/2019 Unit 05ppt

43/48

8/9/2019 Unit 05ppt

44/48

8/9/2019 Unit 05ppt

45/48

8/9/2019 Unit 05ppt

46/48

8/9/2019 Unit 05ppt

47/48

8/9/2019 Unit 05ppt

48/48